|
| Press Releases |
|
 |
|
| Thursday, March 2, 2023 |
|
|
Biogen Japan and Eisai Provide Update on Co-Promotion Of Multiple Sclerosis Treatments In Japan |
| Biogen Japan Ltd. and Eisai Co., Ltd. announced today the termination of the co-promotion agreement that has been in place since January 2018 for Biogen Japan's multiple sclerosis (MS) treatments TECFIDERA (dimethyl fumarate), TYSABRI (natalizumab, genetic recombinant) and AVONEX (interferon beta 1a, genetic recombinant) in Japan as of March 31, 2023. more info >> |
|
| Tuesday, February 28, 2023 |
|
|
Biologics License Application for Lecanemab Designated for Priority Review by China National Medical Products Administration |
| Eisai Co., Ltd. and Biogen Inc. announced today that the Biologics License Application (BLA) for lecanemab, an investigational anti-amyloid beta (Abeta) protofibril antibody, has been designated for Priority Review by the National Medical Products Administration (NMPA) in China. more info >> |
|
| Tuesday, February 21, 2023 |
|
|
Dissolution of Bracco-Eisai Joint Venture |
| Bracco Imaging S.p.A. and Eisai Co., Ltd. announced today that the joint venture regarding the company Bracco-Eisai Co., Ltd. (Ratio of Shares Held: Bracco 51% Eisai 49%), will be dissolved as of March 31, 2023. more info >> |
|
| Monday, January 30, 2023 |
|
|
Lecanemab Receives Priority Review Status in Japan |
| Eisai Co., Ltd. and Biogen Inc. announced today that an application for manufacturing and marketing approval for lecanemab (generic name, U.S. brand name: LEQEMBI), an anti-amyloid-beta (Abeta) protofibril* antibody, in Japan has been designated for Priority Review by the Japanese Ministry of Health, Labour and Welfare (MHLW). more info >> |
|
| Friday, January 27, 2023 |
|
|
Eisai: Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease Accepted by European Medicines Agency |
| Eisai Co., Ltd. and Biogen Inc. announced today that the European Medicines Agency (EMA) has accepted a marketing authorization application (MAA) for lecanemab, an investigational anti-amyloid beta (Abeta) protofibril* antibody, for the treatment of early Alzheimer's disease (mild cognitive impairment due to Alzheimer's disease (AD) and mild AD dementia) with confirmed amyloid pathology, for review following a standard timeline. more info >> |
|
| Thursday, January 19, 2023 |
|
|
Eisai Commences Business Activities at New Pharma Sales Subsidiary in Israel |
| Eisai Co., Ltd. announced today that fully-fledged operations and business activities have begun at Eisai Israel Ltd., a pharmaceutical sales subsidiary recently established in Tel Aviv in the State of Israel (Israel). more info >> |
|
|
Eisai Listed as a Global 100 Most Sustainable Corporation for The Seventh Time Highest Ranked Global Pharmaceutical Company |
| Eisai Co., Ltd. announced that it has been listed in the 2023 Global 100 Most Sustainable Corporations in the World (Global 100), a global ranking by Canada-based media and investment advisory company, Corporate Knights, Inc. more info >> |
|
| Wednesday, January 18, 2023 |
|
|
Eisai Aims to Advance Gastrointestinal Cancer Treatment with Research Across Multiple Tumor Types at ASCO GI 2023 |
| Eisai Co., Ltd. announced today the presentation of research across various types of gastrointestinal cancers during the 2023 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium (#GI23), which is taking place in-person in San Francisco, California and virtually from January 19-21. more info >> |
|
| Monday, January 16, 2023 |
|
|
Eisai Files Marketing Authorization Application for Anti-Amyloid-Beta Protofibril Antibody Lecanemab for Early Alzheimer's Disease in Japan |
| Eisai Co., Ltd. and Biogen Inc. announced today that Eisai has submitted a marketing authorization application for lecanemab. more info >> |
|
| Friday, January 13, 2023 |
|
|
Eisai Launches Renewed Sustainability Page |
| Eisai Co., Ltd. announced that it has renewed the Sustainability page of its corporate website and it is now accessible to the public. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Tay Guan Hin Receives First Ever 2025 AAMS Hall of Fame Visionary Award
Jan 23, 2025 12:10 HKT/SGT
|
|
|
ZeroPath Corp. Launches Next-Generation Code Security Platform Powered by Artificial Intelligence
Jan 23, 2025 10:00 HKT/SGT
|
|
|
TANAKA PRECIOUS METAL TECHNOLOGIES Develops AgSn TLP Sheet, a Sheet-type Bonding Material for Power Semiconductors 
Jan 23, 2025 11:00 JST
|
|
|
Tamkeen Launches 'Bahrain Skills and Gender Parity Accelerator' at Davos
Jan 23, 2025 08:00 HKT/SGT
|
|
|
The Now Corporation (OTC:NWPN) Subsidiary, Green Rain Solar Inc., Explores Selling Development Rights for Solar Farm Project in Greece, NY
Jan 22, 2025 21:00 HKT/SGT
|
|
|
MHI Receives Order for 3 New Series Trainsets (12 Cars) for Seibu Railway's Yamaguchi Line
Jan 22, 2025 17:27 JST
|
|
|
Eisai Listed as a Global 100 Most Sustainable Corporation for The Ninth Time Highest Ranked Global Pharmaceutical Company
Jan 22, 2025 17:18 JST
|
|
|
2nd Annual Operational Excellence & Business Transformation Summit: Operational Excellence in The Age of Digital Transformation, Building A Sustainable and Collaborative Future in Asia
Jan 22, 2025 16:15 HKT/SGT
|
|
|
Introducing the Sonim XP400: a 5g Smartphone Engineered for Demanding Days with Unmatched Durability, Now Available in EMEA and Australia
Jan 22, 2025 15:09 HKT/SGT
|
|
|
ACN Newswire and Corinium Intelligence Present: CISO Perth 2025 - Uniting Western Australia's Top InfoSec Leaders
Jan 22, 2025 14:28 HKT/SGT
|
|
|
ASEAN Finance Innovation Summit 2025: Unlocking the Future of Finance
Jan 22, 2025 14:25 HKT/SGT
|
|
|
Second Hong Kong Shopping Festival gets underway with seminars and consultancy services
Jan 22, 2025 11:54 HKT/SGT
|
|
|
Migrant Workers Honored at Indian New Year Celebrations
Jan 22, 2025 11:40 HKT/SGT
|
|
|
The Now Corporation (OTC: NWPN) Sees Opportunities for Community Solar Projects in California
Jan 21, 2025 21:00 HKT/SGT
|
|
|
Celebrate Chinese New Year with Vibrant Festivities at Spritzer EcoPark
Jan 21, 2025 18:29 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
